Impavido, Drug To Treat Parasitic Disease Leishmaniasis, Backed By FDA Panel
Impavido was granted priority review by the FDA, a status that cuts the review time to six months from the standard 10. Priority
impavido drug treat parasitic disease leishmaniasis back fda panel impavido grant priority review fda status cut review time month standard priority